This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients

This study has been completed.
Information provided by:
University of Zurich Identifier:
First received: December 13, 2007
Last updated: December 17, 2007
Last verified: December 2007

The primary objective of this study is to investigate whether eradication treatment of Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the time to relapse in patients with gastroesophageal reflux disease (GERD).

A relapse is defined by two consecutive symptom scores of the Eraflux questionnaire within 14 days that are equal or above the critical value of 25.

The secondary objectives are

  1. To compare the time to relapse in the two H. pylori positive study groups with the H. pylori negative control group
  2. To compare the pattern of inflammation and atrophy in the two H. pylori positive treatment groups with the naturally H. pylori negative control group at relapse.
  3. All the above objectives analyzed for the efficacy subset that is the per-protocol patients broken down by effective H. pylori-eradication.

Secondary endpoints will be analyzed by the following parameters and their interactions:

  1. Treatment : Eradicated, Non-eradicated, Hp-negative control
  2. Esophagitis at study start: grades 0, A/B and C/D
  3. Gender
  4. Alcohol intake
  5. NSAID/ASA intake (for histological results)

    • Trial with medicinal product

Condition Intervention Phase
Gastroesophageal Reflux Disease (GERD) Drug: Esomeprazole Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD)

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Study Start Date: November 2003
Estimated Study Completion Date: October 2007

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

For inclusion in the study the subject must fulfill all of the following criteria:

  1. Patients aged between 18 and 70 years.
  2. Chronic symptoms (>8 weeks) suggestive for GERD, as defined in Table 2 with or without reflux esophagitis grade A-D (Los Angeles classification)
  3. Indication for endoscopy due to GERD symptoms is given
  4. Written informed consent

Table 2: Lead GERD criteria

For inclusion in the study, all of the following lead GERD criteria should hold:

  • At least one of the symptoms heartburn or regurgitation.
  • At least 8 weeks ongoing symptoms.
  • At least 3 times a week.
  • At least moderate intensity, corresponding to light impairment in daily life and occasional need for drugs.

Exclusion criteria:

Any of the following is regarded as a criterion for exclusion from the study:

  1. Severe organic esophageal disease other than reflux esophagitis (e.g. carcinoma, esophageal stenosis).
  2. Gastric or duodenal ulcers
  3. Patients with visible Barrett's mucosa; no histological confirmation is required for exclusion
  4. History of previous esophageal or gastric surgery
  5. Alcohol or drug abuse
  6. Severe organic or psychiatric disease
  7. Pregnancy or lactation
  8. Women with child-bearing potential if no medically accepted contraceptive measures are used
  9. Contra-indication to amoxicillin, clarithromycin or esomeprazole (Nexium)
  10. Need for concomitant medication which could interfere with the investigational products (substrates of CYP3A4)
  11. Suspected or confirmed poor compliance
  12. Participation in a clinical study within 8 weeks prior to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00574925

University Hospital Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Principal Investigator: Werner Schwizer, MD UniversitaetsSpital Zuerich
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00574925     History of Changes
Other Study ID Numbers: ACH-QBE-0201
Study First Received: December 13, 2007
Last Updated: December 17, 2007

Keywords provided by University of Zurich:
H. pylori

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017